3-Cysteinylacetaminophen (trifluoroacetate salt)
(Synonyms: 3-(cysteine-S-yl)acetaminophen, APAP-Cys) 目录号 : GC42258An acetaminophen-protein adduct
Cas No.:1331891-93-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
3-Cysteinylacetaminophen is an acetaminophen-protein adduct formed during the metabolism of acetaminophen.[1],[2] 3-Cysteinylacetaminophen has been found in isolated human serum following therapeutic and supratherapeutic doses of acetaminophen and in the presence and absence of hepatotoxicity.[3],[4] In mice, 3-cysteinylacetaminophen decreases renal glutathione (GSH) levels, an effect that can be blocked by the γ-glutamyl inhibitor acivicin.
Reference:
[1]. Yoon, E., Babar, A., Choudhary, M., et al. Acetaminophen-induced hepatotoxicity: A comprehensive update. J. Clin. Transl. Hepatol. 4(2), 131-142 (2016).
[2]. Stern, S.T., Bruno, M.K., Horton, R.A., et al. Contribution of acetaminophen-cysteine to acetaminophen nephrotoxicity II. Possible involvement of the γ-glutamyl cycle. Toxicol. Appl. Pharmacol. 202(2), 160-171 (2005).
[3]. Heard, K., Green, J.L., Anderson, V., et al. Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing. Br. J. Clin. Pharmacol. 81(3), 562-568 (2016).
[4]. O'Malley, G.F., Mizrahi, F., Giraldo, P., et al. Protein-derived acetaminophen-cysteine can be detected after repeated supratherapeutic ingestion of acetaminophen in the absence of hepatotoxicity. J. Med. Toxicol. 11(3), 317-320 (2015).
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.6021 mL | 13.0107 mL | 26.0213 mL |
5 mM | 0.5204 mL | 2.6021 mL | 5.2043 mL |
10 mM | 0.2602 mL | 1.3011 mL | 2.6021 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。